神经类病症中的infliximab:一个系统审查和元分析
Siwakorn Chaiyanarm1, Piraya Satiraphan1, Natnasak Apiraksattaykul2
1Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, 10700, Thailand.
Annals of clinical and translational neurology
|December 13, 2023
概括
在治疗神经类固醇症方面,infliximab显示出有前景,改善了临床结果,并允许减少皮质类固醇剂量. 然而,在一些患者中发生了复发,感染是关键的不良事件问题.
科学领域:
- 神经学 神经学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 神经类症是一种罕见的,复杂的神经系统疾病,需要有效的治疗策略.
- 目前神经类固醇症的治疗选择通常涉及皮质类固醇,这可能导致严重的副作用.
- 识别具有提高疗效和安全性概况的新型治疗剂对于管理耐火病例至关重要.
结论:
- 恩弗利克西马布显示出在耐火性神经类症中改善临床结果的显著潜力.
- 该药物可以促进皮质类固醇剂量降低在神经类固醇症患者.
- 感染是不良事件的主要关注点,复发需要监测.
相关概念视频
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
142
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
142
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
168
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
168